6 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 3 | Terminated 3 |
Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) ION269 - Alzheimer Disease, Down Syndrome | Phase 1 | Terminated | Ionis Pharmaceuticals, Inc. | 1 | 2024-12-20 | 2026-02-20 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
| Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome Sunitinib Malate - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 2 | 2008-05-01 | 2024-01-05 |
| Serum-Free Thymus Transplantation in DiGeorge Anomaly Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression - DiGeorge Anomaly | Phase 1 | Terminated | Sumitomo Pharma Switzerland GmbH | 2 | 2008-04-01 | 2022-04-01 |
von Hippel-Lindau Disease (2) · Alzheimer Disease (1) · Carcinoma, Renal Cell (1) · DiGeorge Syndrome (1) · Down Syndrome (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Immunologic Deficiency Syndromes (1) · Netherton Syndrome (1) · Paraganglioma (1) · Pheochromocytoma (1) · Retinitis Pigmentosa (1) · Thymic aplasia (1) · Usher Syndromes (1)
Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Nervous System Diseases (4) · Cardiovascular Diseases (3) · Angiomatosis (2) · Chromosome Disorders (2) · Ciliopathies (2) · Neurocutaneous Syndromes (2) · Neurologic Manifestations (2) · Vascular Diseases (2) · 22q11 Deletion Syndrome (1) · Adenocarcinoma (1) · Blindness (1)
Everolimus (1) · Immunosuppression Therapy (1) · Sunitinib (1) · spartalizumab (1)
Daiichi Sankyo (1) · Ionis Pharmaceuticals, Inc. (1) · National Eye Institute (NEI) (1) · Novartis Pharmaceuticals (1) · Sanofi (1) · Sumitomo Pharma Switzerland GmbH (1)
United States (4) · France (3) · Spain (2) · Czechia (1) · Italy (1) · Japan (1) · Singapore (1)
Catherine Meyerle, MD (1) · Jose-Alain Sahel, MD, PhD (1) · M. Louise Markert, M.D., Ph.D (1) · Richard Weleber, MD (1)
2023 (1), K12HD043494 (1), R01AI047040 (1), R01AI054843 (1)